Previous close | 33.91 |
Open | 32.42 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 32.42 - 33.97 |
52-week range | 23.45 - 37.91 |
Volume | |
Avg. volume | 22,947 |
Market cap | 64.348B |
Beta (5Y monthly) | 0.26 |
PE ratio (TTM) | 48.97 |
EPS (TTM) | 0.68 |
Earnings date | 29 July 2024 - 02 Aug 2024 |
Forward dividend & yield | 0.39 (1.14%) |
Ex-dividend date | 27 Sept 2024 |
1y target est | 35.93 |
TOKYO & BASKING RIDGE, N.J., April 29, 2024--ENHERTU Showed Statistically Significant & Clinically Meaningful Improvement in PFS in HR Positive, HER2 Low mBC Following ET in DESTINY-Breast06
AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.